State Street’s Serina Therapeutics SER Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$24.8K Hold
12,758
﹤0.01% 4203
2025
Q4
$24.4K Hold
12,758
﹤0.01% 4229
2025
Q3
$68.4K Buy
+12,758
New +$67.9K ﹤0.01% 4109
2024
Q1
Sell
-762
Closed -$10.3K 4409
2023
Q4
$10.3K Hold
762
﹤0.01% 4395
2023
Q3
$18.2K Hold
762
﹤0.01% 4454
2023
Q2
$23.9K Hold
762
﹤0.01% 4573
2023
Q1
$17.8K Hold
762
﹤0.01% 4697
2022
Q4
$14.8K Hold
762
﹤0.01% 4770
2022
Q3
$15K Hold
762
﹤0.01% 4861
2022
Q2
$15K Sell
762
-2
-0.3% -$54 ﹤0.01% 4900
2022
Q1
$23K Hold
764
﹤0.01% 4875
2021
Q4
$29K Hold
764
﹤0.01% 4762
2021
Q3
$25K Hold
764
﹤0.01% 4679
2021
Q2
$42K Buy
+764
New +$38.3K ﹤0.01% 4443
2020
Q2
Sell
-8,356
Closed -$273K 3867
2020
Q1
$273K Buy
8,356
+884
+12% +$41.6K ﹤0.01% 3539
2019
Q4
$478K Buy
7,472
+320
+4% +$17.3K ﹤0.01% 3531
2019
Q3
$493K Buy
7,152
+2,206
+45% +$209K ﹤0.01% 3512
2019
Q2
$638K Sell
4,946
-638
-11% -$86.4K ﹤0.01% 3484
2019
Q1
$795K Sell
5,584
-1,063
-16% -$155K ﹤0.01% 3380
2018
Q4
$699K Buy
+6,647
New +$845K ﹤0.01% 3392

Other funds holding SER

State Street's SER Position: Q1 2026 in Review

State Street held its Serina Therapeutics (SER) position steady in Q1 2026 at 12,758 shares worth $24.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4203.

State Street first reported a position in SER in Q4 2018 and has held it in 20 quarters since. The position peaked at $795K in Q1 2019. 25 funds tracked by Wall St. Rank hold SER as of Q1 2026.

  • State Street held 12,758 shares of Serina Therapeutics worth $24.8K as of Q1 2026.
  • State Street left its Serina Therapeutics share count unchanged in Q1 2026.
  • Serina Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #4203 holding.
  • State Street first reported a position in Serina Therapeutics in Q4 2018 and has held it in 20 quarters since.
  • State Street's Serina Therapeutics position peaked at $795K in Q1 2019.
  • 25 funds tracked by Wall St. Rank held Serina Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.